DSLT for Reducing Medication in Glaucoma

April 17, 2026 updated by: The Eye Institute of West Florida

Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Medication Burden in Medically Controlled Patients With Ocular Hypertension or Primary Open Angle Glaucoma

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma.

The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT.

Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Device: Voyager DSLT

Study Type

Observational

Enrollment (Estimated)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Renee Bondurant
Phone Number: 727-450-4668
Email: Renee.Bondurant@eyespecialist.com

Study Locations

United States
- Florida
  - Largo, Florida, United States, 33770
    - Recruiting
    - The Eye Institute of West Florida
    - Contact:
      
      Renee Bondurant
      
      Phone Number: 727-450-4668
      
      Email: Renee.Bondurant@eyespecialist.com
    - Principal Investigator:
      
      Neel Desai, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Child
Adult
Older Adult

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

Adults with ocular hypertension or POAG undergoing DSLT treatment in one or both eyes.

Description

Inclusion Criteria:

Adult patients scheduled to undergo DSLT treatment in one or both eyes.
- Diagnosis of ocular hypertension or primary open angle glaucoma (POAG).
Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg.

Exclusion Criteria:

Previous glaucoma surgeries/interventions:
- Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).
Patients who have undergone cataract surgery within the prior 2 years.
Secondary glaucoma:
- Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.
Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduction in the number of glaucoma medications required to maintain target intraocular pressure (IOP) Time Frame: 6 months post-DSLT treatment	The primary outcome will be assessed by comparing the number of medications needed to maintain target IOP before and after DSLT treatment.	6 months post-DSLT treatment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in intraocular pressure (IOP) from baseline Time Frame: 6 months post-DSLT treatment	IOP will be measured using Goldmann applanation tonometry at each follow-up visit.	6 months post-DSLT treatment
Proportion of eyes needing medication stratified by number of IOP medications required Time Frame: 6 months post-DSLT treatment		6 months post-DSLT treatment
Number and type of Secondary surgical interventions Time Frame: 6 months post-DSLT treatment		6 months post-DSLT treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The Eye Institute of West Florida

Collaborators

Sengi

Investigators

Principal Investigator: Neel Desai, MD, The Eye Institute of West Florida

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 10, 2026

Primary Completion (Estimated)

January 26, 2027

Study Completion (Estimated)

January 26, 2027

Study Registration Dates

First Submitted

January 29, 2026

First Submitted That Met QC Criteria